2004 – Using Buprenorphine in Opioid Treatment Programs: An Exploration of the Situation

2004 Conference Workshop Session
PowerPoint Presentation

  • Allan Cohen, MA, Bay Area Addiction, Research and Treatment, Sherman Oaks, CA
  • Leslie Amass, PHD, Friends Research Institute, Los Angeles, CA
  • Robert Lubran, MS, CSAT, Rockville, MD

Buprenorphine is the newest medication approved by the FDA for the treatment of opioid dependence. Currently, there are increasing interest and efforts to expand the use of buprenorphine into the OTP. This workshop will explore buprenorphine as well as the significant challenges that OTP provides must address to offer buprenorphine as a treatment option in their programs.

Share This